These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 32358546)
21. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631 [TBL] [Abstract][Full Text] [Related]
22. Evaluating the adverse effects of melphalan formulations. Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728 [TBL] [Abstract][Full Text] [Related]
23. Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Parmar SR; Bookout R; Shapiro JF; Tombleson R; Perkins J; Kim J; Yue B; Tomblyn M; Alsina M; Nishihori T Bone Marrow Transplant; 2014 Jun; 49(6):761-6. PubMed ID: 24662419 [TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060 [TBL] [Abstract][Full Text] [Related]
25. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK; Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603 [TBL] [Abstract][Full Text] [Related]
26. Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation. Kowalski KE; Wheeler SE; Adams CB; Voils SA; Richards AI J Oncol Pharm Pract; 2022 Mar; 28(2):274-281. PubMed ID: 33435822 [TBL] [Abstract][Full Text] [Related]
27. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375 [TBL] [Abstract][Full Text] [Related]
28. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153 [TBL] [Abstract][Full Text] [Related]
29. The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning. Ursu SG; Maples S; Williams KJ; Patrus G; Samhouri Y; Fazal S; Mewawalla P; Sadashiv S J Hematol; 2023 Oct; 12(5):201-207. PubMed ID: 37936977 [TBL] [Abstract][Full Text] [Related]
30. Toxicity assessment of concurrent gabapentin/pregabalin administration with high-dose melphalan in autologous hematopoietic cell transplant recipients. Angus J; Cumpston A; Veltri L; Ross KG; Wen S; Dillaman M Support Care Cancer; 2021 Dec; 29(12):7925-7930. PubMed ID: 34191128 [TBL] [Abstract][Full Text] [Related]